Page 25 of 32 · 745 questions tagged clinical-trials.
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. Please show the division. I want to check my own against…
The case in front of me: SURMOUNT-1 · fatigue. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
What I am working with: retatrutide · 40 °C. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched…
The particulars: liraglutide · 37 °C. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned negative…
The particulars: SURMOUNT-2 · constipation · 15 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
The specifics, since they change the answer: oral semaglutide · minus 20 °C. Somebody stated this to me confidently and I would like to check it before repeating it.…
Details up front: STEP 1 · constipation. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I have: SURMOUNT-OSA · tirzepatide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Stated plainly: tirzepatide · room temperature. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I…
For reference: STEP 3 · 2.4 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
Numbers first: a GLP-1 receptor agonist · TRIUMPH-1. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…
What I am working with: cagrilintide · tirzepatide. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…
I have read the prescribing information and it addresses the adjacent case but not this one. I can parse the result. I am less sure what it licenses me to conclude. I…
Concretely: STEP 8 · dizziness. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…
I have three data points across nine months, which I hope is enough to see a trend. I would like the arithmetic checked rather than the conclusion asserted. I have…
Numbers first: TRIUMPH-1 · early satiety · 8 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I have: a GLP-1 receptor agonist · room temperature. I would rather be corrected now than propagate something wrong. I am specifically not interested in a…
The specifics, since they change the answer: 1.7 mg · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan…
Details up front: oral semaglutide · survodutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising…
What I have: REDEFINE-1 · hair thinning · 2.4 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
The particulars: TRIUMPH-1 · 4 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
For reference: 1.7 mg · ecnoglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement than on…
What I am working with: dulaglutide · liraglutide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain…
Numbers first: PIONEER-1 · early satiety. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…